Screener
Viking Therapeutics VKTX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 9:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193315
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accounts payable | 13,931 | (2,110) |
| Accrued expenses | 15,863 | (5,739) |
| Lease liability | (139) | (129) |
| Net cash used in operating activities | (113,976) | (52,331) |
| Cash flows from investing activities | ||
| Purchases of investments | (72,437) | (232,614) |
| Proceeds from maturities of investments | 126,626 | 295,859 |
| Net cash provided by investing activities | 54,189 | 63,245 |
Item 1. Financial Statements
FAQ
- What is Viking Therapeutics's operating cash flow?
- Viking Therapeutics (VKTX) reported operating cash flow of -$113.98M in Q1 2026.
- How has Viking Therapeutics's operating cash flow changed year-over-year?
- Viking Therapeutics's operating cash flow decreased by 117.8% year-over-year, from -$52.33M to -$113.98M.
- What is the long-term trend for Viking Therapeutics's operating cash flow?
- Over 4 years (2021 to 2025), Viking Therapeutics's operating cash flow has grown at a 55.6% compound annual growth rate (CAGR), from -$47.59M to -$278.69M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Viking Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude